Wolfe Research starts Ferrari at Outperform, sees ’solid upside potential’

Wolfe Research initiated coverage of Ferrari (RACE) with an Outperform rating and a €382 price target, citing conservatively set growth targets and expecting above-consensus revenue acceleration from 2027. The firm forecasts FY2027 sales of €8.47B and EBIT of €2.62B vs €8.13B and €2.44B consensus, alongside average selling prices of €550k+ by 2030 supporting >6% top-line CAGR and ~31% EBIT margin. The €382 target implies ~13% upside (33x above-consensus FY2027 EPS of €11.59), with additional upside if the P/E multiple mean-reverts toward a 40x five-year average.

Analysis

The key market mechanism is not "new model hype"; it is that Ferrari’s scarcity model behaves more like a branded luxury asset than a cyclical auto OEM. If the next product cycle sustains pricing discipline, the mix shift should expand EBIT faster than unit growth, which matters because the equity already trades on the assumption that margins are structurally premium. The real beneficiary is RACE’s multiple: a credible re-acceleration in 2027-2030 can justify re-rating from a discount to its own history back toward a premium growth-luxury multiple.

Second-order, this is a relative-value negative for lower-quality luxury automakers with less pricing power and more EV transition drag, notably Porsche/P911.DE and, to a lesser extent, Mercedes-Benz and BMW, where the market has to fund electrification without Ferrari’s brand scarcity. If Ferrari is right that electrification capex is no longer a drag, that also removes a common bear argument and should compress implied risk for future margin dilution. But the market may be extrapolating too quickly: the thesis depends on a long-dated product cadence, so the immediate upside is mostly multiple expansion, while the fundamental inflection is still 12-24 months away.

Contrarian risk: consensus may be underestimating how much of the bull case is already embedded after the stock’s earlier underperformance, and a 33x forward multiple leaves limited room for disappointment if mix, pricing, or delivery cadence slips. Falsifiers are simple: any sign that new models are sold with weaker price realization, EBIT margin stalls below the low-30s target zone, or management sounds more cautious on 2027 demand at the next update. Near-term, this is more a watch-and-buy-on-weakness name than a clean catalyst trade; the market likely needs proof, not another optimistic target revision.

Key Decisions for Investors

• Buy RACE on a 3-6 month horizon only on market-driven weakness; treat it as a quality compounder rather than a catalyst trade. Risk/reward is acceptable if entry is below the stock’s recent re-rating level, but upside should be capped if the market is already discounting the 2027 step-up.
• Pair trade: long RACE / short P911.DE (or Porsche ADR equivalent exposure where available) for 6-12 months. Thesis is Ferrari’s pricing power and margin durability versus Porsche’s greater exposure to EV transition execution risk and weaker scarcity economics.
• If already long RACE, consider scaling with call spreads into the next product-cycle update rather than outright stock. That preserves upside to a multiple re-rate while limiting downside if the market decides 2027 is too far away to pay for today.
• Set a downside falsifier around any management commentary that implies pricing is normalizing or margin expansion is peaking; if that happens, reduce exposure quickly because the valuation case depends on sustained scarcity economics, not volume growth.